THYROTOXICOSIS
8
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G/A SEPP1 Polymorphism
Subacute Thyroiditis in the SARS-CoV-2 Era
Biosignals by Wearables in Thyroid Dysfunction
Therapeutic Plasma Exchange in Thyrotoxicosis
The Association Between Autoimmune or Inflammation and Thyroid Disease
Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
Thiamine Supplement in Patients With Severe Hyperthyroidism
Differential Diagnosis of STA-PSV in Thyrotoxicosis